(Nasdaq: MDCX) Comes Out Hot With A Solid Green Surge (Low Float Profile)

Medicus Pharma Ltd. (Nasdaq: MDCX) is off to a solid green start first thing Tuesday.

*Disseminated on behalf of Medicus Pharma Ltd. (Nasdaq: MDCX) Comes Out Hot With A Solid Green Surge (Low Float Profile) August 19th Greetings, Friend! Medicus Pharma Ltd. (Nasdaq: MDCX) is off to a solid green start first thing Tuesday. Could this be due to MDCX's news continuing to spread from earlier this month? If you haven't yet, read it now: Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vac-cines. Another thing to think about is the size of MDCX's float. At roughly 2.6Mn shares, volatility potential could rear its head in the matter of moments. Spend a moment thumbing through my initial report below and consider (Nasdaq: MDCX) for your radar. ----- Within the rapidly evolving life sciences industry, certain companies are starting to draw attention for their work on groundbreaking treatments designed to address significant unmet medical needs. Among them, a relatively lesser-known company’s subsidiary is moving forward with the development of a dissolvable microneedle patch that administers chemotherapy directly into skin tumors, with the goal of transforming the way basal cell carcinoma is treated today. Currently undergoing clinical trials in both the U.S. and the UAE, this innovative, non-invasive method may provide a more patient-friendly and less invasive option compared to surgical or systemic approaches. The company is also expanding through acquisitions, including a late-stage UK biotech focused on advanced prostate therapies, signaling a broader ambition in areas with high unmet needs. Factor in a low float (under 3Mn shares), two analyst targets indicating significant upside potential, and a major acquisition proceeding forward, this Nasdaq profile may soon be due for some serious buzz. Take a moment to consider Medicus Pharma Ltd. (Nasdaq: MDCX) for your radar. Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. The company is actively engaged in multiple countries, spread over three continents. Complete Company Details - Medicus Pharma Ltd. (Nasdaq: MDCX) Focus: Accelerating clinical development of novel therapeutics across multiple countries and continents. Specialty: Moving innovative therapies quickly through clinical stages. About SkinJect (Medicus Pharma's Wholly Owned Subsidiary) Product: Patented dissolvable microneedle patch (D-MNA) for non-melanoma skin cancer, especially basal cell carcinoma. Mechanism: Delivers doxorubicin directly to tumor via transdermal microneedles, aiming to replace invasive Mohs surgery with a painless, office-based treatment. Rights: Exclusive global development and commercialization rights from University of Pittsburgh and Carnegie Mellon since 2016. Clinical Progress Phase 1 (2021): Demonstrated safety, tolerability, and some complete responses. Phase 2: IND submitted to FDA in January 2024; patient recruitment began August 2024 at 9 US sites. Interim analysis (March 2025): Over 60% complete clinical response; trial expanded from 60 to 90 patients. SkinJect Value Proposition Innovation: Patented, non-invasive microneedle patch for direct drug delivery to skin tumors. Market: BCC is the most common cancer globally; North American market projected at $15Bn by 2030. Clinical Results: Positive safety and efficacy data in early trials, with ongoing Phase 2 showing promise. Leadership: Experienced management and board with oncology and drug development expertise. Medicus Pharma (Nasdaq: MDCX) is positioned to impact standards of care in both human and veterinary medicine, with ongoing clinical and regulatory milestones. Find Sources Here: MDCX Presentation. MDCX Website. ----- 5 Potential Catalysts Could Provide (Nasdaq: MDCX) With A Breakout Spark! #1. A Low Float Scenario: With roughly 2.60Mn shares in its float, volatility potential could be heightened at the drop of a hat. #2. Two Analyst Targets Suggest MDCX May Be Undervalued. Take a look at these two targets found over at MarketBeat: From Monday's close, these targets project a potential upside of over 1,100% and 750%, respectively. #3. Next Generation Vac-cine Development Collaboration Could Accelerate Global Hea.lthcare Technology Access. Medicus Pharma Ltd. and Helix Nanotechnologies Inc. have signed a non-binding MOU to develop thermostable infectious disease vac-cines by combining HelixNano’s proprietary mRNA platform with Medicus’ microneedle array delivery technology. This promising collaboration aims to create global scale, needle-free vac-cines, potentially reducing costs and improving patient access. Early research, supported by the University of Pittsburgh, will soon begin, focusing on loading mRNA vac-cines into clinical-grade microneedle arrays for safety and efficacy studies, positioning Medicus for significant advances in va-ccine delivery. #4. Medicus Pharma’s FDA Submission Strengthens Path Toward Advanced Skin Cancer Therapy. Medicus Pharma Ltd. has submitted a Type C meeting request to the FDA to accelerate development of its innovative Dissolvable Doxorubicin-containing Microneedle Arrays (D-MNA) for treating basal cell carcinoma (BCC). Backed by strong Phase 1 safety results and promising interim Phase 2 efficacy data showing over 60% clinical clearance, the Company aims to align with the FDA on trial design, dosage, and endpoints With expanded U.S. and European trial sites, plus new UAE studies, Medicus is advancing global innovation. #5. Medicus Pharma Announces Definitive Agreement To Acquire Antev Ltd. Medicus Pharma has entered a definitive agreement to acquire UK-based Antev Ltd. This acquisition will expand Medicus’s pipeline into late-stage urology therapeutics, opening access to a $6Bn market and diversifying its portfolio, which could accelerate growth and strengthen its position in the biotech sector. ----- Medicus Pharma Ltd. (Nasdaq: MDCX) has risen up to take over the top spot on my watchlist. Stay focused for updates coming soon.  All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 08/14/2025 and ending on 08/20/2025 to publicly disseminate information about (MDCX:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid seven thousand five hundred USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid fifteen thousand USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (MDCX:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/mdcx-tz9r4/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Update Profile | Our Privacy Policy | Constant Contact Data Notice